Antisense Therapeutics Ltd
ASX:ANP
Antisense Therapeutics Ltd
Cash from Financing Activities
Antisense Therapeutics Ltd
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Antisense Therapeutics Ltd
ASX:ANP
|
Cash from Financing Activities
-AU$85.3k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Cash from Financing Activities
-AU$431.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Cash from Financing Activities
AU$3.6m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-18%
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Cash from Financing Activities
AU$36.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
11%
|
CAGR 10-Years
46%
|
|
Probiotec Ltd
ASX:PBP
|
Cash from Financing Activities
-AU$11.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Cash from Financing Activities
AU$231.6k
|
CAGR 3-Years
-70%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Antisense Therapeutics Ltd's Cash from Financing Activities?
Cash from Financing Activities
-85.3k
AUD
Based on the financial report for Jun 30, 2023, Antisense Therapeutics Ltd's Cash from Financing Activities amounts to -85.3k AUD.